[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Bio-Rad Labs\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":76},{"warningLetters":4,"total":75},[5,32,52],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},992,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-03-25T04:00:00Z\">03\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-20T04:00:00Z\">03\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbpi-labs-llc-699533-03202025\">BPI Labs, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs\u002FMisbranded \u003Cbr \u002F>\r\n","","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chandra Kasireddy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BPI Labs, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>12393 S Belcher Road Ste 450\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Largo\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33773\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:chandrak@belcherpharma.com\"> chandrak@belcherpharma.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 20, 2025\u003C\u002Fp>\u003Cp>RE: 699533\u003C\u002Fp>\u003Cp>Dear Mr. Kasireddy:\u003C\u002Fp>\u003Cp>This letter concerns your firm’s, BPI Labs, LLC’s (BPI’s), distribution of its Epinephrine Chloride Nasal Solution 1 mg\u002FmL, 10 mL. The U.S. Food and Drug Administration (FDA) reviewed your product, including product labeling.\u003C\u002Fp>\u003Cp>Your Epinephrine Chloride Nasal Solution product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), 331(d). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>This product is also misbranded under section 502(i) of the FD&amp;C Act, 21 U.S.C. 352(i). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Epinephrine Chloride Nasal Solution is a drug within the meaning of section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1) because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body of man or other animals. Specifically, this product is intended for use as a nasal decongestant\u002Fvasoconstrictor. Examples of claims observed on BPI’s Epinephrine Chloride Nasal Solution labeling, including the product label, that provide evidence of its intended use (as defined in 21 C.F.R. 201.128) include, but may not be limited to, the following:\u003C\u002Fp>\u003Cul>\u003Cli>“Vasoconstrictor for Topical Application”\u003C\u002Fli>\u003Cli>“For use as a nasal decongestant”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce unless it is the subject of an application approved by FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a).\u003C\u002Fp>\u003Cp>FDA is not aware of any adequate and well-controlled clinical trials in published literature that support a determination that Epinephrine Chloride Nasal Solution is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which the product would be legally marketed without an approved application. Further, no FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for this product. Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). The introduction or delivery for introduction of unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” BPI’s unapproved Epinephrine Chloride Nasal Solution product is labeled for use as a topical nasal decongestant, to be “[a]ppl[ied] locally as drops or spray, or with a sterile swab, as required.” Notwithstanding its intended use as a topical drug, the container closure system for BPI’s unapproved epinephrine nasal solution appears identical to that used for BPI’s FDA-approved epinephrine injection product, which is a small glass vial with a flip-off cap that protects a needle penetrable seal. This type of glass vial is a container closure that is customarily used by drug manufacturers to package small volumes (e.g., 10 or 20 mL) of sterile injectable drugs intended for parenteral administration (including intravenous administration). The Epinephrine Chloride Nasal Solution glass vial and its similarity to the glass vials for your FDA-approved Epinephrine Injection may mislead users into believing the product is intended for injection and thereby, increase the risk of erroneous administration. FDA has received reports of confusion between your firm’s unapproved Epinephrine Chloride Nasal Solution and FDA-approved Epinephrine Injection resulting in the erroneous preparation of your unapproved nasal product for parenteral administration.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As such, your unapproved Epinephrine Chloride Nasal Solution product, packaged in a container that appears identical to containers ordinarily used to package sterile injectable drugs, is a misbranded drug under section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1).\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of a misbranded drug violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you no longer manufacture or market the above-mentioned product, your response should indicate this, including the reasons that, and the date on which, you ceased production. Also, please indicate your progress in updating the drug listing eDRLS files in accordance with 21 C.F.R. 207.57(b). If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot address any violations within fifteen working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “699533” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On January 16, 2025, FDA published a news release titled “FDA warns health care professionals not to use epinephrine nasal solutions from BPI Labs and Endo USA,” see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-health-care-professionals-not-use-epinephrine-nasal-solutions-bpi-labs-and-endo-usa. This news release warns health care professionals not to use unapproved epinephrine nasal solutions due to risk of administration error.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nChandra Kasireddy\n\nRecipient Title\n\nChief Operating Officer\n\nBPI Labs, LLC\n\n12393 S Belcher Road Ste 450\n\nLargo, FL 33773\n\nUnited States\n\nchandrak@belcherpharma.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 20, 2025\nRE: 699533\nDear Mr. Kasireddy:\nThis letter concerns your firm’s, BPI Labs, LLC’s (BPI’s), distribution of its Epinephrine Chloride Nasal Solution 1 mg\u002FmL, 10 mL. The U.S. Food and Drug Administration (FDA) reviewed your product, including product labeling.\nYour Epinephrine Chloride Nasal Solution product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), 331(d). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nThis product is also misbranded under section 502(i) of the FD&C Act, 21 U.S.C. 352(i). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nUnapproved New Drug Violations\nEpinephrine Chloride Nasal Solution is a drug within the meaning of section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1) because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body of man or other animals. Specifically, this product is intended for use as a nasal decongestant\u002Fvasoconstrictor. Examples of claims observed on BPI’s Epinephrine Chloride Nasal Solution labeling, including the product label, that provide evidence of its intended use (as defined in 21 C.F.R. 201.128) include, but may not be limited to, the following:\n“Vasoconstrictor for Topical Application”\n“For use as a nasal decongestant”\nIn general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce unless it is the subject of an application approved by FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a).\nFDA is not aware of any adequate and well-controlled clinical trials in published literature that support a determination that Epinephrine Chloride Nasal Solution is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which the product would be legally marketed without an approved application. Further, no FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for this product. Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). The introduction or delivery for introduction of unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranding Violations\nSection 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” BPI’s unapproved Epinephrine Chloride Nasal Solution product is labeled for use as a topical nasal decongestant, to be “[a]ppl[ied] locally as drops or spray, or with a sterile swab, as required.” Notwithstanding its intended use as a topical drug, the container closure system for BPI’s unapproved epinephrine nasal solution appears identical to that used for BPI’s FDA-approved epinephrine injection product, which is a small glass vial with a flip-off cap that protects a needle penetrable seal. This type of glass vial is a container closure that is customarily used by drug manufacturers to package small volumes (e.g., 10 or 20 mL) of sterile injectable drugs intended for parenteral administration (including intravenous administration). The Epinephrine Chloride Nasal Solution glass vial and its similarity to the glass vials for your FDA-approved Epinephrine Injection may mislead users into believing the product is intended for injection and thereby, increase the risk of erroneous administration. FDA has received reports of confusion between your firm’s unapproved Epinephrine Chloride Nasal Solution and FDA-approved Epinephrine Injection resulting in the erroneous preparation of your unapproved nasal product for parenteral administration.1 As such, your unapproved Epinephrine Chloride Nasal Solution product, packaged in a container that appears identical to containers ordinarily used to package sterile injectable drugs, is a misbranded drug under section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1).\nThe introduction or delivery for introduction into interstate commerce of a misbranded drug violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you no longer manufacture or market the above-mentioned product, your response should indicate this, including the reasons that, and the date on which, you ceased production. Also, please indicate your progress in updating the drug listing eDRLS files in accordance with 21 C.F.R. 207.57(b). If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot address any violations within fifteen working days, state the reason for the delay and the time within which you will do so.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “699533” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n________________\n1 On January 16, 2025, FDA published a news release titled “FDA warns health care professionals not to use epinephrine nasal solutions from BPI Labs and Endo USA,” see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-health-care-professionals-not-use-epinephrine-nasal-solutions-bpi-labs-and-endo-usa. This news release warns health care professionals not to use unapproved epinephrine nasal solutions due to risk of administration error.","BPI Labs, LLC","bpi-labs-llc-699533-03202025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbpi-labs-llc-699533-03202025","2026-10-26T08:08:08.409063+00:00","Warning Letter","Issued","2025-03-25","699533","Drugs","Chandra Kasireddy","2026-08-19T16:54:51.026+00:00","Via Email","2025-03-20",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":19,"fei_number":20,"letter_url":44,"updated_at":45,"action_type":23,"case_status":24,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":20,"issuing_office":38,"recipient_name":20,"body_fetched_at":49,"delivery_method":50,"recipient_title":20,"reference_number":20,"action_taken_date":51,"medical_device_id":20,"response_letter_date":20},803,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2025-07-01T04:00:00Z\">07\u002F01\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-29T04:00:00Z\">05\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbad-drip-labs-inc-708507-05292025\">Bad Drip Labs Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Bad Drip Labs Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>465 Paul Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Suite 4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rochester\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>14624-4779\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 29, 2025&nbsp;&nbsp;&nbsp;&nbsp;\u003Cbr>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Bad Drip Labs Inc. sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. &nbsp;Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. &nbsp;See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. &nbsp;Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. &nbsp;For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribute to customers in the United States e-liquid products that lack a marketing authorization order, including: Bad Drip Sweet Tooth 60mL, 3mg.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. &nbsp;These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). &nbsp;In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. &nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. &nbsp;You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.&nbsp;\u003Cbr>\u003Cbr>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. &nbsp;If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501217, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>FDA Center for Tobacco Products\u003Cbr>c\u002Fo Document Control Center\u003Cbr>Building 71, Room G335\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement&nbsp;\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>[Cc: As appropriate]&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nTobacco\n\nRecipient:\n\nBad Drip Labs Inc.\n\n465 Paul Road\n\nSuite 4\n\nRochester, NY 14624-4779\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 29, 2025\n\nWARNING LETTER\n\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Bad Drip Labs Inc. sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribute to customers in the United States e-liquid products that lack a marketing authorization order, including: Bad Drip Sweet Tooth 60mL, 3mg.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501217, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002Fs\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\n[Cc: As appropriate]","Bad Drip Labs Inc.","bad-drip-labs-inc-708507-05292025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbad-drip-labs-inc-708507-05292025","2026-10-26T08:08:00.355918+00:00","2025-07-01","708507","Tobacco","2026-08-19T16:37:55.696+00:00","VIA UPS","2025-05-29",{"id":53,"raw":54,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":20,"letter_url":65,"updated_at":66,"action_type":23,"case_status":24,"posted_date":67,"marcs_cms_no":68,"product_type":69,"closeout_date":20,"issuing_office":58,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":20,"reference_number":73,"action_taken_date":74,"medical_device_id":20,"response_letter_date":20},389,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2025-12-23T05:00:00Z\">12\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-09T05:00:00Z\">12\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsv-labs-corporation-716503-12092025\">SV Labs Corporation\u003C\u002Fa>","Center for Veterinary Medicine","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-26\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Graham Orriss\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SV Labs Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>480 Airport Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Watsonville\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95076\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-26\u003C\u002Fp>\u003Cp>December 9, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Orriss:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, SV Labs Prescott Corporation, FEI 2130687, at 1115 Dexter Street North, Prescott, Wisconsin, from June 10 to 13, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your July 7, 2025, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not adequately investigate out-of-specification (OOS) results associated with your over-the-counter (OTC) human and animal drug products contract manufactured by your facility.\u003C\u002Fp>\u003Cp>For example, an OTC SPF 30 sunscreen lotion human drug product lot failed your total aerobic microbial count specification with a “too numerous to count” (TNTC) result. Your firm released the lot to your customer without investigating the cause of the microbial failure. During a previous FDA inspection, your firm was also cited for releasing drug product lots with failing microbial results without conducting proper investigations.\u003C\u002Fp>\u003Cp>On September 17, 2025, FDA held a teleconference with you to discuss SPF 30 sunscreen lotion human drug product, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During that call, you agreed to voluntarily recall this lot.\u003C\u002Fp>\u003Cp>Your firm identified \u003Cem>Burkholderia cepacia complex\u003C\u002Fem> \u003Cem>(BCC)\u003C\u002Fem> in an OTC topical fungicide animal drug product lot with production line swab samples confirming growth of gram-negative rods consistent with \u003Cem>BCC\u003C\u002Fem>. While your firm rejected the affected lot and increased cleaning and sanitization of the production line, your investigation was inadequate. You failed to extend the investigation to other potentially impacted batches manufactured on the contaminated equipment and did not adequately evaluate the water system as a potential source of contamination, despite documented water system failures. Since 2023, your firm has recorded numerous water system failures, including uninvestigated microbial tests with TNTC results.\u003C\u002Fp>\u003Cp>In your response, you acknowledge past inconsistent compliance with your OOS investigation procedures, which you state has been corrected. We note your additional commitments to conduct a retrospective review of manufacturing records to identify other lots with OOS results that you released to the market. You also committed to implementing process improvement corrective action and preventive actions (CAPAs), updating standard operating procedures (SOPs), and training personnel.\u003C\u002Fp>\u003Cp>Your response is inadequate because it lacks a thorough market suitability analysis for the released sunscreen lot with failing results. Your analysis should include an assessment of risk to consumers and justification for leaving a potentially contaminated product on the market. Additionally, your 12-month retrospective review timeframe is insufficient and should be expanded to cover all products within expiry dates to identify products still in use by consumers. Your response also fails to adequately assess the significance of \u003Cem>BCC\u003C\u002Fem> contamination across your entire product portfolio, particularly given your water system’s documented history of failing microbial test results.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all manufactured drug products currently in the U.S. market and within expiry as of the date of this letter, and a report summarizing the findings of the analysis. If such review reveals substandard quality drug products (including lots with OOS results), take rapid corrective actions, such as notifying customers and market action.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting BCC testing of retain samples to determine the quality of all batches of drug products distributed to the United States that are within expiry as of the date of this letter, and a summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and market action.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequately scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has not demonstrated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water that you use as a component is suitable for aqueous-based drug product manufacturing and, at a minimum, meets the United States Pharmacopeia (USP) \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water monograph and appropriate microbial limits.\u003C\u002Fp>\u003Cp>Your legacy \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system included two dead legs that create stagnant areas, fostering biofilm development and microbial contamination. This risk is compounded by your documented history of water system and drug product microbial failures which include TNTC results. These fundamental design deficiencies posed contamination risks to all products manufactured using this water.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that your facility experienced significant water system deficiencies that required comprehensive remediation efforts and installation of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system capable of producing water suitable for its intended purpose. Your response also includes corrective actions such as decommissioning your legacy system, implementing controlled data collection forms, retraining staff on good documentation practices, updating water monitoring SOPs and conducting an impact analysis of products manufactured prior to the improvements.\u003C\u002Fp>\u003Cp>Your response is inadequate. Although you commit to decommissioning the legacy system after validating your new water system, your response does not provide supportive documentation to demonstrate that the new water system is validated for its intended use. Additionally, your response lacks adequate details to ensure that your sampling, testing, and monitoring procedures can meet USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water monograph requirements.\u003C\u002Fp>\u003Cp>Pharmaceutical water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the water system.\u003Cbr>o Validation report for the water system obtained after an appropriately designed system has been installed. Include the system validation protocol, the complete test results, and the final validation report.\u003C\u002Fli>\u003Cli>Your total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacks process validation studies to demonstrate reproducibility and control of manufacturing processes to ensure uniform product quality. Your firm's extensive history of assay failures in both animal and human over-the-counter drug products, requiring reprocessing indicates poor manufacturing control. Additionally, your firm’s cleaning procedures for shared equipment, particularly filling equipment used to manufacture multiple products including drug products, have not been validated.\u003C\u002Fp>\u003Cp>In your response, you commit to validating your OTC drug product manufacturing processes and equipment cleaning procedures in established timeframes. You also state that you will conduct a retrospective product review.\u003C\u002Fp>\u003Cp>Your response is inadequate. It lacks sufficient details regarding your planned retrospective review of drug products manufactured using unvalidated processes with no clarification on whether the analysis will encompass lots that failed assay testing or underwent reprocessing. Furthermore, while your firm recognizes the use of multiple potent and chemically diverse substances at the facility, your response fails to identify these substances and does not commit to performing a risk assessment to determine if these compounds are processed on shared equipment.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for process performance qualification and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s) and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning.\u003C\u002Fli>\u003Cli>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Appropriate controls were exercised over computer systems to ensure only authorized personnel make changes to master production and control records or other records (21 CFR 211.68(b)).\u003C\u002Fli>\u003Cli>Adequate laboratory controls were established with proper specifications, standards, sampling plans, and test procedures to ensure materials and drug products meet required identity, strength, quality, and purity standards (21 CFR 211.160(b)).\u003C\u002Fli>\u003Cli>An adequate written stability testing program for drug products (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Laboratory records included complete data from all required tests for compliance with specifications and standards (21 CFR 211.194(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you provide corrective actions for each deficiency with specific timeframes.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to address the systemic quality deficiencies identified during the inspection. The observed lapses, including but not limited to laboratory controls, documentation practices, and data integrity controls, many of which were also identified during previous inspections, indicate fundamental weaknesses in the QU’s oversight function. The proposed corrective actions do not adequately demonstrate how you will strengthen quality oversight to ensure ongoing compliance with CGMP requirements.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, you should engage a consultant, qualified as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2130687 and ATTN: Rory Geyer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Jill P. Furman, J.D.\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research&nbsp;\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dillard H Woody Jr.\u003Cbr>Acting Drug Compliance Director\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-26\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Graham Orriss\n\nRecipient Title\n\nChief Executive Officer\n\nSV Labs Corporation\n\n480 Airport Boulevard\n\nWatsonville, CA 95076\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWarning Letter 320-26-26\nDecember 9, 2025\nDear Mr. Orriss:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, SV Labs Prescott Corporation, FEI 2130687, at 1115 Dexter Street North, Prescott, Wisconsin, from June 10 to 13, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your July 7, 2025, response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm did not adequately investigate out-of-specification (OOS) results associated with your over-the-counter (OTC) human and animal drug products contract manufactured by your facility.\nFor example, an OTC SPF 30 sunscreen lotion human drug product lot failed your total aerobic microbial count specification with a “too numerous to count” (TNTC) result. Your firm released the lot to your customer without investigating the cause of the microbial failure. During a previous FDA inspection, your firm was also cited for releasing drug product lots with failing microbial results without conducting proper investigations.\nOn September 17, 2025, FDA held a teleconference with you to discuss SPF 30 sunscreen lotion human drug product, lot (b)(4). During that call, you agreed to voluntarily recall this lot.\nYour firm identified Burkholderia cepacia complex (BCC) in an OTC topical fungicide animal drug product lot with production line swab samples confirming growth of gram-negative rods consistent with BCC. While your firm rejected the affected lot and increased cleaning and sanitization of the production line, your investigation was inadequate. You failed to extend the investigation to other potentially impacted batches manufactured on the contaminated equipment and did not adequately evaluate the water system as a potential source of contamination, despite documented water system failures. Since 2023, your firm has recorded numerous water system failures, including uninvestigated microbial tests with TNTC results.\nIn your response, you acknowledge past inconsistent compliance with your OOS investigation procedures, which you state has been corrected. We note your additional commitments to conduct a retrospective review of manufacturing records to identify other lots with OOS results that you released to the market. You also committed to implementing process improvement corrective action and preventive actions (CAPAs), updating standard operating procedures (SOPs), and training personnel.\nYour response is inadequate because it lacks a thorough market suitability analysis for the released sunscreen lot with failing results. Your analysis should include an assessment of risk to consumers and justification for leaving a potentially contaminated product on the market. Additionally, your 12-month retrospective review timeframe is insufficient and should be expanded to cover all products within expiry dates to identify products still in use by consumers. Your response also fails to adequately assess the significance of BCC contamination across your entire product portfolio, particularly given your water system’s documented history of failing microbial test results.\nIn response to this letter, provide:\nA retrospective, independent review of all manufactured drug products currently in the U.S. market and within expiry as of the date of this letter, and a report summarizing the findings of the analysis. If such review reveals substandard quality drug products (including lots with OOS results), take rapid corrective actions, such as notifying customers and market action.\nAn action plan and timelines for conducting BCC testing of retain samples to determine the quality of all batches of drug products distributed to the United States that are within expiry as of the date of this letter, and a summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and market action.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequately scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\n2. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\nYour firm has not demonstrated that the (b)(4) water that you use as a component is suitable for aqueous-based drug product manufacturing and, at a minimum, meets the United States Pharmacopeia (USP) (b)(4) Water monograph and appropriate microbial limits.\nYour legacy (b)(4) water system included two dead legs that create stagnant areas, fostering biofilm development and microbial contamination. This risk is compounded by your documented history of water system and drug product microbial failures which include TNTC results. These fundamental design deficiencies posed contamination risks to all products manufactured using this water.\nIn your response, you acknowledge that your facility experienced significant water system deficiencies that required comprehensive remediation efforts and installation of a new (b)(4) water system capable of producing water suitable for its intended purpose. Your response also includes corrective actions such as decommissioning your legacy system, implementing controlled data collection forms, retraining staff on good documentation practices, updating water monitoring SOPs and conducting an impact analysis of products manufactured prior to the improvements.\nYour response is inadequate. Although you commit to decommissioning the legacy system after validating your new water system, your response does not provide supportive documentation to demonstrate that the new water system is validated for its intended use. Additionally, your response lacks adequate details to ensure that your sampling, testing, and monitoring procedures can meet USP (b)(4) Water monograph requirements.\nPharmaceutical water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\nIn response to this letter, provide:\nA comprehensive remediation plan for the design, control, and maintenance of the water system.\no Validation report for the water system obtained after an appropriately designed system has been installed. Include the system validation protocol, the complete test results, and the final validation report.\nYour total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) Water USP monograph specifications and appropriate microbial limits.\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm lacks process validation studies to demonstrate reproducibility and control of manufacturing processes to ensure uniform product quality. Your firm's extensive history of assay failures in both animal and human over-the-counter drug products, requiring reprocessing indicates poor manufacturing control. Additionally, your firm’s cleaning procedures for shared equipment, particularly filling equipment used to manufacture multiple products including drug products, have not been validated.\nIn your response, you commit to validating your OTC drug product manufacturing processes and equipment cleaning procedures in established timeframes. You also state that you will conduct a retrospective product review.\nYour response is inadequate. It lacks sufficient details regarding your planned retrospective review of drug products manufactured using unvalidated processes with no clarification on whether the analysis will encompass lots that failed assay testing or underwent reprocessing. Furthermore, while your firm recognizes the use of multiple potent and chemically diverse substances at the facility, your response fails to identify these substances and does not commit to performing a risk assessment to determine if these compounds are processed on shared equipment.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for process performance qualification and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s) and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nAppropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning.\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\nAppropriate controls were exercised over computer systems to ensure only authorized personnel make changes to master production and control records or other records (21 CFR 211.68(b)).\nAdequate laboratory controls were established with proper specifications, standards, sampling plans, and test procedures to ensure materials and drug products meet required identity, strength, quality, and purity standards (21 CFR 211.160(b)).\nAn adequate written stability testing program for drug products (21 CFR 211.166(a)).\nLaboratory records included complete data from all required tests for compliance with specifications and standards (21 CFR 211.194(a)).\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn your response, you provide corrective actions for each deficiency with specific timeframes.\nYour response is inadequate because it fails to address the systemic quality deficiencies identified during the inspection. The observed lapses, including but not limited to laboratory controls, documentation practices, and data integrity controls, many of which were also identified during previous inspections, indicate fundamental weaknesses in the QU’s oversight function. The proposed corrective actions do not adequately demonstrate how you will strengthen quality oversight to ensure ongoing compliance with CGMP requirements.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, you should engage a consultant, qualified as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2130687 and ATTN: Rory Geyer.\nSincerely,\n\u002FS\u002F\nJill P. Furman, J.D.\nDirector\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nDillard H Woody Jr.\nActing Drug Compliance Director\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine","SV Labs Corporation","sv-labs-corporation-716503-12092025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsv-labs-corporation-716503-12092025","2026-10-26T08:10:08.439344+00:00","2025-12-23","716503","Animal & VeterinaryDrugs Over-the-Counter Drugs","Mr. Graham Orriss","2026-08-19T07:20:29.104+00:00","Via Electronic Mail - Return Receipt Requested","320-26-26","2025-12-09",3,{"510k":77,"classification":78,"enforcement":79,"event":80,"event_backfill":81,"pma":82,"warning_letter":83},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-20T04:00:32.497+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]